Updates are available Correction dated 2025-07-01
Click to view Correction: https://doi.org/10.1038/s41467-025-61578-4
-
Authors
Silveira, André Bortolini https://orcid.org/0000-0003-3375-1081
Houy, Alexandre https://orcid.org/0000-0001-6267-2353
Ganier, Olivier
Özemek, Begüm
Vanhuele, Sandra https://orcid.org/0009-0005-1305-4643
Vincent-Salomon, Anne https://orcid.org/0000-0001-5754-5771
Cassoux, Nathalie
Mariani, Pascale
Pierron, Gaelle https://orcid.org/0000-0002-2536-7680
Leyvraz, Serge https://orcid.org/0000-0002-5705-6799
Rieke, Damian https://orcid.org/0000-0003-0027-7977
Picca, Alberto
Bielle, Franck https://orcid.org/0000-0001-6564-6388
Yaspo, Marie-Laure https://orcid.org/0000-0002-9555-9979
Rodrigues, Manuel https://orcid.org/0000-0002-5443-0802
Stern, Marc-Henri https://orcid.org/0000-0002-8100-2272
- License Information
-
More Information
Article History
Received: 22 January 2024
Accepted: 1 November 2024
First Online: 14 November 2024
Change Date: 22 April 2025
Change Type: Update
Change Details: In this article André Bortolini Silveira was not listed as a co-corresponding author. The original article has been corrected.
Change Date: 1 July 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-025-61578-4
Competing interests
: D. Rieke reports advisory agreement with BeiGene and Bayer, honoraria from Bristol Myers Squibb, Bayer and Roche, research support from Seagen, and personal fees from Bayer and Johnson & Johnson, all outside the submitted work. A. Picca reports personal fees from AstraZeneca and Servier, all outside the submitted work. F. Bielle reports funding of research from Abbvie, service agreement for research contracted between his institution and Treefrog Therapeutics as well as Owkin, personal fees from Bristol Myers Squibb and a next-of-kin employed by Bristol Myers Squibb, all outside the submitted work. M.L. Yaspo is COO/CSO and shareholder of Alacris Theranostics without conflict of interest with the submitted work. M. Rodrigues reports non-financial support from AstraZeneca and Merck Sharp and Dohme, grants from Daiichi Sankyo, personal fees from AstraZeneca, Immunocore, Merck Sharp and Dohme and GlaxoSmithKline, all outside the submitted work. M.-H. Stern reports grants from Immunocore and Bionano, and royalties from Myriad Genetics, all outside the submitted work. The remaining authors have no conflict of interest to declare.
